Equities

Arcus Biosciences Inc

RCUS:NYQ

Arcus Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)17.85
  • Today's Change1.39 / 8.44%
  • Shares traded1.11m
  • 1 Year change+11.49%
  • Beta0.9133
Data delayed at least 15 minutes, as of Nov 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7591,009499
Total Receivables, Net4239747
Total Inventory------
Prepaid expenses301916
Other current assets, total------
Total current assets8311,0671,262
Property, plant & equipment, net143135137
Goodwill, net------
Intangibles, net------
Long term investments107129182
Note receivable - long term------
Other long term assets14147.73
Total assets1,0951,3451,592
LIABILITIES
Accounts payable172010
Accrued expenses767652
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total9197104
Total current liabilities184193166
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total449495584
Total liabilities633688750
SHAREHOLDERS EQUITY
Common stock1,3111,2060.01
Additional paid-in capital----1,118
Retained earnings (accumulated deficit)(849)(542)(275)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(7)(1.26)
Total equity462657841
Total liabilities & shareholders' equity1,0951,3451,592
Total common shares outstanding767371
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.